1H-1lambda~6~,4-Benzothiazepine-1,1-dione | 650584-07-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫氮卓类
• 英文名称: 1H-1lambda~6~,4-Benzothiazepine-1,1-dione
• 英文别名: 1λ6,4-benzothiazepine 1,1-dioxide
• CAS: 650584-07-9
• 化学式: C₉H₇NO₂S
• 分子量: 193.22
• InChiKey: IVGHNDNOFMTFMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
  申请人：FRICK Wendelin

  公开号：US20080207592A1

  公开（公告）日：2008-08-28

  The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.

  该发明涉及公式（A）的化合物及其生理上可接受的盐。该化合物可用作降血脂药物等。
• 1,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMIC
  申请人：FRICK Wendelin

  公开号：US20080207534A1

  公开（公告）日：2008-08-28

  The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.

  本发明涉及公式（A）的化合物，以及其生理上可接受的盐。该化合物适用于例如降血脂。
• [EN] HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES<br/>[FR] 1,4-BENZOTHIAZEPINE-1,1-DIOXYDES A ACTION HYPOLIPIDEMIQUE
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：WO1996005188A1

  公开（公告）日：1996-02-22

  (EN) The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.(FR) Cette invention se rapporte à de nouveaux composés hypolipidémiques, représentés par la formule (I), à des procédés et à de nouveaux intermédiaires servant à leur préparation, à des compositions pharmaceutiques qui les contiennent et à leur utilisation en médecine, particulièrement pour la prophylaxie et le traitement d'états hyperlipidémiques, tels que l'athérosclérose.

  该发明涉及化学式（I）的新型降脂化合物，以及用于制备它们的新型中间体和工艺，含有它们的药物组合物，以及它们在医学上的使用，特别是在预防和治疗高脂血症状况，如动脉粥样硬化。
• Hypolipidemic 1,4-benzothiazepine-1,-dioxides
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0864582A3

  公开（公告）日：1998-10-21

  The present invention is concerned with new hypolipidemic compounds, with processes and novel intermediates for their preparation, with pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.Compounds of the formula (I): wherein R1 to R10 and X are a defined.

  本发明涉及新的降血脂化合物、制备它们的工艺和新型中间体、含有它们的药物组合物以及它们在医学中的用途，特别是在预防和治疗高血脂症（如动脉粥样硬化）中的用途： 其中 R1 至 R10 和 X 是已定义的。
• Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
  申请人：Starke Ingemar

  公开号：US20050101611A1

  公开（公告）日：2005-05-12

  An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor in the ileum and the HMG Co A reductase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.

  一种口服药物制剂，包含一种回肠胆汁酸转运抑制剂化合物（IBAT 抑制剂）、一种 HMG Co-A 还原酶抑制剂和一种治疗上可接受的载体，其特征在于该制剂旨在将 IBAT 抑制剂送入回肠，并将 HMG Co-A 还原酶抑制剂非特异性地送入消化道。IBAT 抑制剂化合物和 HMG Co-A 还原酶抑制剂还可与胆汁酸粘合剂联合使用，以减轻 IBAT 抑制剂化合物治疗可能产生的副作用，例如腹泻。胆汁酸粘合剂可配制成结肠释放剂。